Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Mares

Showing results (11-20 of 111) with videos related to

Pageof 12
Sort By:
General Physiology and Biophysics|September 29, 2011
Modulations of behavioral consequences of minor cortical ischemic lesion by application of free radicals scavengersKateryna Deykun, Marie Pometlova, Barbora Schutova, et al.
Shock (Augusta, Ga.)|December 25, 2008
Recent progress of proteomics in critical illnessThomas Karvunidis, Jan Mares, Visith Thongboonkerd, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 17, 2020
Alemtuzumab: Rare serious adverse events of a high-efficacy drugHans-Peter Hartung, Jan Mares, Michael H Barnett
Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia|April 8, 2006
Applications of new laboratory marker assays in neurological diagnoses - a pilot studyDavid Stejskal, Jitka Vavrousková, Jan Mares, et al.
Current Opinion in Neurology|April 16, 2019
Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigmBruce A C Cree, Jan Mares, Hans-Peter Hartung
Artificial Organs|June 5, 2019
Proteins adsorbed to a polysulfone hemodialysis membrane under heparin and citrate anticoagulation regimensJan Mares, Zdenek Tuma, Jiri Moravec, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 4, 2021
Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy RiskHans-Peter Hartung, Jan Mares, Sven G Meuth, et al.
Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia|March 22, 2016
Proteomic approaches to the study of renal mitochondriaZdenek Tuma, Jitka Kuncova, Jan Mares, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 3, 2021
Correction to: Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy RiskHans-Peter Hartung, Jan Mares, Sven G Meuth, et al.
Neuro Endocrinology Letters|February 2, 2015
Influence of arsenic and cyanobacteria co-exposure on plasmatic parameters of rainbow trout (Oncorhynchus mykiss W.)Radovan Kopp, Jan Mares, Zdenka Soukupova, et al.
Pageof 12

Showing results (11-20 of 111) with videos related to

Sort By:
Pageof 12
General Physiology and Biophysics|September 29, 2011
Modulations of behavioral consequences of minor cortical ischemic lesion by application of free radicals scavengersKateryna Deykun, Marie Pometlova, Barbora Schutova, et al.
Shock (Augusta, Ga.)|December 25, 2008
Recent progress of proteomics in critical illnessThomas Karvunidis, Jan Mares, Visith Thongboonkerd, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 17, 2020
Alemtuzumab: Rare serious adverse events of a high-efficacy drugHans-Peter Hartung, Jan Mares, Michael H Barnett
Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia|April 8, 2006
Applications of new laboratory marker assays in neurological diagnoses - a pilot studyDavid Stejskal, Jitka Vavrousková, Jan Mares, et al.
Current Opinion in Neurology|April 16, 2019
Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigmBruce A C Cree, Jan Mares, Hans-Peter Hartung
Artificial Organs|June 5, 2019
Proteins adsorbed to a polysulfone hemodialysis membrane under heparin and citrate anticoagulation regimensJan Mares, Zdenek Tuma, Jiri Moravec, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 4, 2021
Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy RiskHans-Peter Hartung, Jan Mares, Sven G Meuth, et al.
Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia|March 22, 2016
Proteomic approaches to the study of renal mitochondriaZdenek Tuma, Jitka Kuncova, Jan Mares, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 3, 2021
Correction to: Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy RiskHans-Peter Hartung, Jan Mares, Sven G Meuth, et al.
Neuro Endocrinology Letters|February 2, 2015
Influence of arsenic and cyanobacteria co-exposure on plasmatic parameters of rainbow trout (Oncorhynchus mykiss W.)Radovan Kopp, Jan Mares, Zdenka Soukupova, et al.
Pageof 12